Navigation Links
BioMarin Announces Third Quarter 2009 Financial Results
Date:10/28/2009

arges of $5.9 million in 2009 and $4.1 million in 2008; (4) Kuvan approval milestones received of $31.5 million earned in 2008; (5) the gross margin of the initial Aldurazyme product transfer to Genzyme of $2.3 million associated with the restructuring of BioMarin/Genzyme LLC in the first quarter of 2008; (6) gain on the sale of equity investments of $1.6 million in 2009 and (7) income tax effect of $0.3 million and $2.2 million in 2009 and 2008, respectively. The reconciliation of these measures to the estimated GAAP net income is detailed in the table provided at the end of the press release.

BioMarin believes that this non-GAAP information is useful to investors, taken in conjunction with BioMarin's GAAP information because it provides additional information regarding the performance of BioMarin's core ongoing business, Naglazyme, Kuvan and Aldurazyme and development of its pipeline. By providing information about both the overall GAAP financial performance and the non-GAAP measures that focus on continuing operations, the company believes that the additional information enhances investors' overall understanding of the company's business and prospects for the future. Further, the company uses both the GAAP and the non-GAAP results and expectations internally for its operating, budgeting and financial planning purposes.

Diluted Earnings Per Share Calculation

The calculation of GAAP diluted earnings per share for all of the 2009 periods presented and non-GAAP diluted earnings per share for the third quarter and first nine months of 2008 reflect the theoretical exclusion of the interest expense from net earnings that would no longer be incurred if the Company's convertible notes were converted into shares as their impact is considered anti-dilutive. Non-GAAP diluted earnings per share for the third quarter and first nine months of 2009 include 16.0 million shares related to the Company's convertible notes due in April 2017
'/>"/>

SOURCE BioMarin Pharmaceutical Inc.
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18

Related medicine technology :

1. BioMarin to Present at the Oppenheimer Healthcare Conference
2. BioMarin Acquires Huxley Pharmaceuticals, Inc.
3. BioMarin Initiates Phase 2 Clinical Study of PEG-PAL in PKU
4. BioMarin Initiates Phase 1/2 Clinical Trial for GALNS for Morquio A Syndrome
5. BioMarin Announces Positive Results From Phase 2A Clinical Study of 6R-BH4 in Sickle Cell Disease
6. BioMarin Initiates Phase 1 Clinical Study of PEG-PAL in PKU
7. BioMarin Announces FDA Approval for Kuvan
8. BioMarin Partner AnGes MG, Inc. Submits BLA to Japanese Ministry of Health
9. Rigel Announces Presentations at Two Investor Conferences
10. Onyx Pharmaceuticals Announces Third Quarter 2009 Financial Results Teleconference and Webcast
11. STAAR Surgical Announces Third Quarter 2009 Earnings Release Date and Conference Call
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/18/2013)... , June 18, 2013 Valeant Pharmaceuticals International, ... has priced its previously announced public offering of common ... will issue 23,529,412 common shares at a price of ... $2.0 billion. The Company will file a final prospectus ... S-3 and will make a similar filing with the ...
(Date:6/18/2013)... June 18, 2013  It has become apparent ... Seating and Mobility, a subsidiary company of The ... repair. This appears to be due to the ... field service employees.  (Logo: ... of these clients are complex mobility users with ...
(Date:6/18/2013)... GARDEN CITY, N.Y. , June 18, 2013 ... announced that it has entered into an exclusive ... and Mid-Atlantic regions with eWellness Corporation ("EWC") for ... "An easy to use physical therapy program ... of diabetes and cardiovascular disease," said Chris ...
Breaking Medicine Technology:Valeant Pharmaceuticals Prices Public Offering Of Common Shares 2Valeant Pharmaceuticals Prices Public Offering Of Common Shares 3Valeant Pharmaceuticals Prices Public Offering Of Common Shares 4Millennium HealthCare Signs Exclusive Distribution Agreement with eWellness Corporation for Northeast and Mid-Atlantic Regions 2Millennium HealthCare Signs Exclusive Distribution Agreement with eWellness Corporation for Northeast and Mid-Atlantic Regions 3
... Aug. 26 Semafore Pharmaceuticals Inc.,announced data presented ... Cancer in Washington, D.C., showing additional antiangiogenic,activity of ... VEGF and Bv8 signaling., PI3K is part ... pathway that,has been shown to play a major ...
... 26 XTENT, Inc.,(Nasdaq: XTNT ) today announced ... trial was published in the most recent issue of ... was,Dr. Pieter R. Stella, M.D., of University Medical Center ... Investigators from 13 clinical,sites across Europe., The one-year ...
Cached Medicine Technology:SF1126, Semafore's PI3 Kinase Inhibitor, Found to Block Angiogenic Signaling From Both VEGF and Bv8 in Multiple Cell Lines 2SF1126, Semafore's PI3 Kinase Inhibitor, Found to Block Angiogenic Signaling From Both VEGF and Bv8 in Multiple Cell Lines 3XTENT Announces CUSTOM II Data Selected for Publication in EuroIntervention 2XTENT Announces CUSTOM II Data Selected for Publication in EuroIntervention 3XTENT Announces CUSTOM II Data Selected for Publication in EuroIntervention 4
(Date:6/19/2013)... 2013 Weight gain and obesity have ... concerns including heart disease, kidney failure and high blood ... excess and unnecessary fat, have many people searching for ... hCG diets to not only allow patients to ... also aim to reduce the risk for many weight-related ...
(Date:6/19/2013)... To survive when your plane goes down on a combat mission, ... the most important item in a survival kit is not a ... Kleyne Hour Power of Water radio show, Orr stated that in ... ahead of guns or even food. , According to Orr, the ... carry on planes in Vietnam. He was the only Navy pilot ...
(Date:6/19/2013)... New York,NY (PRWEB) June 19, 2013 ... company officials at SizeItUp formally announced the ... This smartly renovated van is the latest entry in ... for the year 2013. The completely redesigned 2012 Nissan ... the automobile lovers and critics alike. , Provided with ...
(Date:6/19/2013)... McGuff Pharmaceuticals, Inc. continues to ... (ANDA) for Hydroxyprogesterone Caproate Injection, USP 250mg/mL, 5mL, multiple ... fomerly known as Delalutin™. We are providing this ... approval and market introduction dates for McGuff’s Hydroxyprogesterone Caproate ... our pending ANDA, to date, McGuff has responded to ...
(Date:6/19/2013)... 2013 Audibel Hearing Center is ... tinnitus patients, the A2 with Multiflex Tinnitus Technology. ... ringing in the ears. Although bothersome, tinnitus usually ... body. , Using their patent-pending Multiflex Tinnitus Technology, ... comforting sound stimulus that resonates through the patient’s ...
Breaking Medicine News(10 mins):Health News:hCGTreatments / Diet Doc hCG Diets & Weight Loss Plans Offers New Fast Weight Loss Programs for Patients Suffering with Health Care Concerns 2Health News:hCGTreatments / Diet Doc hCG Diets & Weight Loss Plans Offers New Fast Weight Loss Programs for Patients Suffering with Health Care Concerns 3Health News:Vietnam Navy Pilot Reveals to Radio Host Sharon Kleyne That He Carried Extra Water Not a Gun in Survival Kit 2Health News:Rim Fitments Expert, SizeItUp Comes Up With Database Integrations For The 2012 Nissan NV 2Health News:Current Progress Towards ANDA Approval of Hydroxyprogesterone Caproate Injection, USP 2Health News:Audibel Hearing Center Introduces A2 with Multiflex Tinnitus Technology 2
... boost emotional well-being in hard times , , THURSDAY, May ... women may actually overspend to try to cheer themselves up, ... found that 79 percent said they,d go on a shopping ... listed "depression" and 60 percent listed "feeling a bit low" ...
... to Improve CBO Modeling and Information for PolicymakersWASHINGTON, ... Fight Chronic Disease policy briefing on Capitol Hill, ... James C. Capretta, M.A., released a white paper, ... Diseases: The Current Context and Potential Enhancements." ...
... Hospitalist Company, Inc. (Nasdaq: IPCM ), a leading national physician group practice company, announced today that management ... New York City., ... ... ...
... CITY, Calif., May 21 Genomic Health, Inc. (Nasdaq: ... will present results from three studies at the American ... May 29 - June 2, 2009, at the Orange ... markets the widely-adopted Onco type DX(R) breast cancer ...
... 21 Celator Pharmaceuticals today announced that it ... Inc. (Nasdaq: CEPH ). The ... application of Celator,s proprietary technology to an ongoing ... agreement provides an opportunity to leverage the technology ...
... the importance of hearing healthPISCATAWAY, N.J., May 21 ... Hearing Month in Times Square from ... air a 30-second hearing loss awareness video every hour on ... addition, 18 Siemens representatives will be in Times Square and ...
Cached Medicine News:Health News:Shop 'Til You Drop: You May Feel Better 2Health News:National Coalition Hosts Event to Examine Costs Projections for Chronic Diseases 2Health News:National Coalition Hosts Event to Examine Costs Projections for Chronic Diseases 3Health News:IPC The Hospitalist Company, Inc. to Present at Citi's 2009 Healthcare Services Day 2Health News:Genomic Health to Present Multiple New Studies at the American Society of Clinical Oncology Annual Meeting 2Health News:Genomic Health to Present Multiple New Studies at the American Society of Clinical Oncology Annual Meeting 3Health News:Celator(R) Pharmaceuticals Initiates Research Agreement With Cephalon, Inc. 2Health News:Siemens Promotes May is Better Speech and Hearing Month on America's Largest Stage 2Health News:Siemens Promotes May is Better Speech and Hearing Month on America's Largest Stage 3
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
Medicine Products: